A Randomized 3 Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR A) in Patients = 70 Years Old With Untreated Mantle Cell Lymphoma
For more information about the trial above please contact the study team:
Principal Investigator, Irl Greenwell, at email@example.com, or please call +1 843-792-4759.
Study Coordinator, Christina Paskal, at firstname.lastname@example.org.
Trial opened at the following institutions: Medical University of South Carolina